Senseonics Eversense News Today

The FDA has approved extending the use of an implantable continuous glucose monitoring sensor for up to 6 months for adults with diabetes, according to a company press release. Senseonics’s Eversense E3 continuous glucose monitoring system is a fully implantable third-generation sensor that connects to a removable smart transmitter and mobile app displaying glucose values, trends and

Why Senseonics Is An Intriguing Speculative Buy At These Levels InvestorPlace 1 hr ago © Source: Shutterstock an image of a microscope There’s a place in most portfolios for small speculative positions. In this regard, I think investors may want to consider  Senseonics Holdings (NYSEAMERICAN: © Provided by InvestorPlace an image of a microscope Senseonics is a medical technology company focused on providing implantable glucose monitoring (CGM) systems for those with diabetes. The co...